FDA’s acceptance and Priority Review of ifinatamab deruxtecan (I-DXd)

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Post author:Bree Clare
Post published:April 22, 2026
Post category:Small cell lung cancer

Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA's acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More